Persistence of immunity 18–19 years after vaccination against hepatitis B in 2 cohorts of vaccinees primed as infants or as adolescents in Italy. Issue 5 (4th May 2017)

• Record Type: Journal Article
• Authors: Romanò, Luisa; Galli, Cristina; Tagliacarne, Catia; Tosti, Maria Elena; Velati, Claudio; Fomiatti, Laura; Chironna, Maria; Coppola, Rosa Cristina; Cuccia, Mario; Mangione, Rossana; Marrone, Fosca; Negrone, Francesco Saverio; Parlato, Antonino; Zotti, Carla Maria; Mele, Alfonso; Zanetti, Alessandro Remo
• Is Part Of: Human vaccines & immunotherapeutics. Volume 13:Issue 5(2017)
• Page Start: 981
• Page End: 985
• Publication Date: 2017-05-04
• Subjects: hepatitis B -- HBV -- immune memory -- long-term immunity -- vaccination; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2017.1264795
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: This study was aimed at assessing the anti-HBs persistence and immune memory 18–19 y after vaccination against hepatitis B in healthy individuals primed as infants or adolescents. We enrolled 405 teenagers (Group A) vaccinated as infants, and 409 young adults (Group B) vaccinated as adolescents. All vaccinees were tested for anti-HBs and anti-HBc antibodies; those found anti-HBc positive were further tested for HBsAg and HBV DNA. Eight individuals belonging to Group B were positive for anti-HBc alone, and were excluded from analysis. Individuals with anti-HBs concentration ≥ 10 mIU/ml were considered protected while those with anti-HBs concentration <10 mIU/ml were offered a booster dose and re-tested 2 weeks later. Overall, 67.9% individuals showed anti-HBs concentrations ≥ 10 mIU/ml (48.9% in Group A vs 87.0% in Group B, p < 0.001). The antibody geometric mean concentration (GMC) was higher in Group B than in Group A (102.5 mIU/ml vs 6.9 mIU/ml; p < 0.001). When boosted, 94.2% of vaccinees with anti-HBs <10 mIU/ml belonging to Group A and 94.7% to Group B showed an anamnestic response. Post-booster GMCs were similar in both groups (477.9 mIU/ml for Group A vs 710.0 mIU/ml for Group B, p = n.s.). Strong immunological memory persists for at least 18–19 y after immunization of infants or adolescents with a primary course of vaccination. Thus, booster doses are not needed at this time, but additional follow up is required to assess the long-life longevity of protection.